Biotech Values

[DewDiligence]

Combretastatin is on my watch list, but I am more concerned about Macugen and Lucentis. So let me turn this around and ask why you find Combretastatin such a compelling threat; i.e. why do you think it will be either safer or more effective than other anti-angio drug candidates?

BTW: if there is ever a head-to-head trial of Squalamine vs Combretastatin, the trial will be known as “Shark vs Bark.”